by Clinical Neuropsychologist Online | Friday, November 22, 2024 | Dementia
Abstract BACKGROUND This study examines whether phosphorylated plasma Tau217 ratio (pTau217R) can predict tau accumulation in different brain regions, as measured by positron emission tomography (PET) standardized uptake value ratio (SUVR), for staging...
by Clinical Neuropsychologist Online | Friday, November 22, 2024 | Dementia
Abstract INTRODUCTION While the role of apolipoprotein E (APOE) ε4 in Alzheimer’s disease (AD) susceptibility has been studied extensively, much less is known about the differences in disease presentation in APOE ε4 carriers versus non-carriers. METHODS To help...
by Clinical Neuropsychologist Online | Thursday, November 21, 2024 | Dementia
Abstract BACKGROUND Peak-width of skeletonized mean diffusivity (PSMD), a neuroimaging marker of cerebral small vessel disease (SVD), has shown excellent instrumental properties. Here, we extend our work to perform a biological validation of PSMD. METHODS We included...
by Clinical Neuropsychologist Online | Wednesday, November 20, 2024 | Dementia
Abstract Amyloid-PET quantification through the tracer-independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid-β (Aβ) pathology in Alzheimer’s disease (AD) patients. The AMYPAD consortium set out to integrate...
by Clinical Neuropsychologist Online | Tuesday, November 19, 2024 | Dementia
Abstract INTRODUCTION Patterns of signal from tau positron emission tomography (tau-PET) confined to the medial temporal lobe (MTL) or extended into the neocortex may be relevant for Alzheimer’s disease (AD) research if they are linked to differential biomarker...
